AstraZeneca Given Hold Rating at Deutsche Bank (AZN)
AstraZeneca (LON:AZN)‘s stock had its “hold” rating reiterated by investment analysts at Deutsche Bank in a note issued to investors on Monday, StockRatingsNetwork reports. They currently have a GBX 3,425 ($55.26) price objective on the stock. Deutsche Bank’s price objective points to a potential upside of 7.00% from the company’s current price.
A number of other firms have also recently commented on AZN. Analysts at AlphaValue reiterated a “reduce” rating on shares of AstraZeneca (LON:AZN) in a research note to investors on Thursday. They now have a GBX 3,256 ($52.53) price target on the stock. Separately, analysts at Credit Suisse reiterated an “underperform” rating on shares of AstraZeneca (LON:AZN) in a research note to investors on Wednesday, September 25th. They now have a GBX 3,130 ($50.50) price target on the stock. Finally, analysts at BNP Paribas reiterated a “neutral” rating on shares of AstraZeneca (LON:AZN) in a research note to investors on Tuesday, September 17th. They now have a GBX 3,200 ($51.63) price target on the stock. Eleven research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of GBX 3,227.97 ($52.08).
Shares of AstraZeneca (LON:AZN) traded up 0.45% on Monday, hitting GBX 3215.50. 2,108,910 shares of the company’s stock traded hands. AstraZeneca has a 1-year low of GBX 2786.00 and a 1-year high of GBX 3544.50. The stock has a 50-day moving average of GBX 3215.42 and a 200-day moving average of GBX 3252.57. The company’s market cap is £40.258 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.